Concepts (314)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Chagas Disease | 3 | 2018 | 155 | 1.76 | Why? |
| Malaria, Falciparum | 4 | 2018 | 377 | 1.44 | Why? |
| Relapsing Fever | 2 | 2017 | 14 | 1.43 | Why? |
| Enterococcus | 2 | 2021 | 73 | 1.02 | Why? |
| Mycoses | 2 | 2020 | 589 | 0.75 | Why? |
| West Nile Fever | 1 | 2021 | 166 | 0.75 | Why? |
| Borrelia | 1 | 2017 | 39 | 0.71 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2021 | 323 | 0.65 | Why? |
| Emigrants and Immigrants | 4 | 2018 | 888 | 0.65 | Why? |
| Cholera | 1 | 2019 | 189 | 0.62 | Why? |
| Macrophage Activation Syndrome | 1 | 2020 | 342 | 0.62 | Why? |
| Invasive Pulmonary Aspergillosis | 2 | 2020 | 634 | 0.61 | Why? |
| Onchocerciasis | 1 | 2017 | 64 | 0.61 | Why? |
| Candidemia | 1 | 2020 | 353 | 0.60 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.59 | Why? |
| Travel | 7 | 2021 | 7220 | 0.55 | Why? |
| Communicable Diseases, Imported | 3 | 2021 | 843 | 0.54 | Why? |
| DNA, Bacterial | 1 | 2017 | 835 | 0.51 | Why? |
| Endocarditis, Bacterial | 1 | 2018 | 344 | 0.50 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2009 | 260 | 0.49 | Why? |
| Italy | 22 | 2021 | 38444 | 0.47 | Why? |
| Malaria | 2 | 2019 | 1097 | 0.46 | Why? |
| Refugees | 2 | 2017 | 809 | 0.42 | Why? |
| Leishmania | 2 | 2011 | 28 | 0.41 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2021 | 1380 | 0.40 | Why? |
| Leishmaniasis, Cutaneous | 2 | 2011 | 48 | 0.39 | Why? |
| Hepatitis B | 1 | 2018 | 888 | 0.39 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.37 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.37 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.36 | Why? |
| Influenza Vaccines | 2 | 2020 | 2941 | 0.33 | Why? |
| Trypanosoma cruzi | 2 | 2018 | 133 | 0.32 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.31 | Why? |
| Family | 1 | 2020 | 2909 | 0.30 | Why? |
| Cryoglobulinemia | 2 | 2017 | 144 | 0.30 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 952 | 0.28 | Why? |
| Hepatitis C, Chronic | 3 | 2017 | 973 | 0.26 | Why? |
| Sepsis | 1 | 2021 | 3517 | 0.26 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 533 | 0.25 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.24 | Why? |
| Antimalarials | 4 | 2019 | 2505 | 0.23 | Why? |
| Coinfection | 3 | 2021 | 6820 | 0.23 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 711 | 0.23 | Why? |
| Polypharmacology | 1 | 2021 | 33 | 0.23 | Why? |
| Humans | 62 | 2021 | 930598 | 0.22 | Why? |
| Male | 40 | 2021 | 367725 | 0.22 | Why? |
| Vasculitis | 2 | 2017 | 691 | 0.21 | Why? |
| Sex Ratio | 1 | 2021 | 69 | 0.21 | Why? |
| Hypotrichosis | 1 | 2020 | 40 | 0.21 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.21 | Why? |
| Multiple Chronic Conditions | 1 | 2021 | 115 | 0.21 | Why? |
| HIV Infections | 4 | 2018 | 11620 | 0.21 | Why? |
| Spinal Puncture | 1 | 2000 | 95 | 0.21 | Why? |
| Plasmodium malariae | 1 | 2019 | 17 | 0.20 | Why? |
| Middle Aged | 32 | 2021 | 270681 | 0.20 | Why? |
| Meningitis, Cryptococcal | 1 | 2000 | 79 | 0.20 | Why? |
| Skin Diseases, Genetic | 1 | 2020 | 65 | 0.20 | Why? |
| Transaminases | 1 | 2020 | 152 | 0.20 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.20 | Why? |
| Vibrio cholerae | 1 | 2019 | 44 | 0.20 | Why? |
| Cross Infection | 2 | 2020 | 8675 | 0.19 | Why? |
| Respiration, Artificial | 3 | 2021 | 22116 | 0.19 | Why? |
| Drug Interactions | 3 | 2021 | 1653 | 0.19 | Why? |
| Voriconazole | 1 | 2021 | 206 | 0.19 | Why? |
| Intracranial Hypertension | 1 | 2000 | 111 | 0.19 | Why? |
| Prescriptions | 1 | 2020 | 258 | 0.19 | Why? |
| El Salvador | 1 | 2018 | 27 | 0.19 | Why? |
| Medical History Taking | 1 | 2021 | 350 | 0.19 | Why? |
| Streptococcus | 1 | 2018 | 76 | 0.18 | Why? |
| Aspergillus fumigatus | 1 | 2021 | 239 | 0.18 | Why? |
| Pulmonary Aspergillosis | 2 | 2021 | 408 | 0.18 | Why? |
| Somalia | 1 | 2017 | 62 | 0.18 | Why? |
| Drug Tolerance | 1 | 2018 | 100 | 0.18 | Why? |
| Female | 33 | 2021 | 380317 | 0.18 | Why? |
| Nitroimidazoles | 1 | 2018 | 69 | 0.18 | Why? |
| Bolivia | 1 | 2018 | 187 | 0.17 | Why? |
| Africa, Eastern | 1 | 2017 | 90 | 0.17 | Why? |
| Adult | 22 | 2021 | 244371 | 0.17 | Why? |
| Sudan | 1 | 2017 | 166 | 0.17 | Why? |
| Quinine | 1 | 2017 | 56 | 0.17 | Why? |
| Calcinosis | 1 | 2020 | 240 | 0.17 | Why? |
| Bacteriophages | 1 | 2020 | 268 | 0.17 | Why? |
| Proteinuria | 1 | 2020 | 474 | 0.16 | Why? |
| Serum Albumin | 1 | 2020 | 571 | 0.16 | Why? |
| Risk Adjustment | 1 | 2021 | 730 | 0.16 | Why? |
| Lung Diseases, Fungal | 1 | 2017 | 167 | 0.16 | Why? |
| Aged | 22 | 2021 | 215776 | 0.16 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.15 | Why? |
| Fluorenes | 1 | 2016 | 101 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.15 | Why? |
| Heart Valve Diseases | 1 | 2020 | 355 | 0.15 | Why? |
| Zona Pellucida | 1 | 1994 | 10 | 0.15 | Why? |
| Genome, Bacterial | 1 | 2019 | 446 | 0.15 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.15 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.15 | Why? |
| Drug Prescriptions | 2 | 2021 | 1062 | 0.14 | Why? |
| Klebsiella Infections | 1 | 2020 | 466 | 0.14 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.14 | Why? |
| Doxycycline | 1 | 2017 | 307 | 0.14 | Why? |
| Oligospermia | 1 | 1994 | 9 | 0.14 | Why? |
| Diagnostic Errors | 1 | 2021 | 865 | 0.14 | Why? |
| Antiviral Agents | 9 | 2020 | 41703 | 0.14 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.13 | Why? |
| Lasers | 1 | 1994 | 132 | 0.13 | Why? |
| Microscopy | 1 | 2017 | 414 | 0.13 | Why? |
| Ghana | 1 | 2017 | 763 | 0.13 | Why? |
| Europe | 4 | 2021 | 12702 | 0.13 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.13 | Why? |
| Benzimidazoles | 1 | 2016 | 275 | 0.13 | Why? |
| Transgender Persons | 1 | 2018 | 322 | 0.13 | Why? |
| Immunoassay | 2 | 2021 | 4485 | 0.13 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.12 | Why? |
| Bangladesh | 1 | 2019 | 1620 | 0.12 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.12 | Why? |
| Immunocompromised Host | 1 | 2009 | 5150 | 0.12 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.12 | Why? |
| Switzerland | 1 | 2020 | 2738 | 0.12 | Why? |
| Latin America | 1 | 2018 | 1721 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Leishmania donovani | 1 | 2011 | 15 | 0.11 | Why? |
| Polymorphism, Genetic | 1 | 2019 | 1074 | 0.11 | Why? |
| Sustained Virologic Response | 3 | 2017 | 378 | 0.11 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.11 | Why? |
| Polymerase Chain Reaction | 4 | 2019 | 6740 | 0.11 | Why? |
| Vaccination Coverage | 1 | 2020 | 1249 | 0.11 | Why? |
| Fatal Outcome | 1 | 2021 | 3438 | 0.11 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 1261 | 0.11 | Why? |
| Fertilization in Vitro | 1 | 1994 | 330 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.11 | Why? |
| Genomics | 2 | 2020 | 3118 | 0.11 | Why? |
| Hepatitis B, Chronic | 1 | 2017 | 616 | 0.11 | Why? |
| Antirheumatic Agents | 3 | 2020 | 3023 | 0.10 | Why? |
| Shock, Septic | 1 | 2020 | 1313 | 0.10 | Why? |
| Leishmaniasis, Visceral | 1 | 2011 | 85 | 0.10 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.10 | Why? |
| Infertility, Male | 1 | 1994 | 322 | 0.10 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.10 | Why? |
| Diagnosis | 1 | 2009 | 71 | 0.09 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.09 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 1510 | 0.09 | Why? |
| Anti-Bacterial Agents | 3 | 2020 | 10083 | 0.09 | Why? |
| Respiratory Insufficiency | 2 | 2020 | 7301 | 0.09 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.09 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.09 | Why? |
| Hydroxychloroquine | 3 | 2020 | 12447 | 0.09 | Why? |
| Dengue | 1 | 2021 | 1565 | 0.09 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.09 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.09 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.09 | Why? |
| Workplace | 1 | 2020 | 2075 | 0.08 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.08 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.08 | Why? |
| Heparin | 1 | 2020 | 2600 | 0.08 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.08 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.08 | Why? |
| Arrhythmias, Cardiac | 1 | 2020 | 2510 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.08 | Why? |
| Electrocardiography | 1 | 2020 | 3957 | 0.08 | Why? |
| Autoimmune Diseases | 1 | 2020 | 1996 | 0.08 | Why? |
| Adolescent | 6 | 2020 | 86841 | 0.08 | Why? |
| General Surgery | 1 | 2018 | 1472 | 0.07 | Why? |
| Ambulatory Care Facilities | 1 | 2017 | 2063 | 0.07 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.07 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Fever | 2 | 2020 | 7795 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Phylogeny | 2 | 2020 | 13341 | 0.07 | Why? |
| Rheumatic Diseases | 1 | 2020 | 2675 | 0.07 | Why? |
| Pandemics | 12 | 2020 | 389249 | 0.07 | Why? |
| Echocardiography | 1 | 2018 | 3661 | 0.07 | Why? |
| Internationality | 1 | 2017 | 3297 | 0.07 | Why? |
| Arthritis, Rheumatoid | 1 | 2017 | 2043 | 0.07 | Why? |
| Autopsy | 2 | 2020 | 3495 | 0.07 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.07 | Why? |
| AIDS-Associated Nephropathy | 1 | 2003 | 18 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| AIDS Dementia Complex | 1 | 2003 | 48 | 0.06 | Why? |
| Inflammatory Bowel Diseases | 1 | 2020 | 3209 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.06 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.06 | Why? |
| Recurrence | 3 | 2019 | 3675 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Pharmacokinetics | 1 | 2021 | 41 | 0.06 | Why? |
| Administration, Oral | 2 | 2020 | 2340 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Hyaline Membrane Disease | 1 | 2020 | 16 | 0.06 | Why? |
| Potentially Inappropriate Medication List | 1 | 2021 | 55 | 0.05 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Brazil | 1 | 2018 | 12582 | 0.05 | Why? |
| Genome, Protozoan | 1 | 2019 | 11 | 0.05 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.05 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.05 | Why? |
| Viral Nonstructural Proteins | 1 | 2017 | 4810 | 0.05 | Why? |
| Neutrophil Infiltration | 1 | 2020 | 201 | 0.05 | Why? |
| Emigration and Immigration | 1 | 2005 | 501 | 0.05 | Why? |
| Leukocidins | 1 | 2019 | 47 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Chromatography, Affinity | 1 | 2021 | 310 | 0.05 | Why? |
| Microsatellite Repeats | 1 | 2019 | 99 | 0.05 | Why? |
| Global Health | 2 | 2017 | 13911 | 0.05 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Coccidioidomycosis | 1 | 2017 | 47 | 0.04 | Why? |
| Lost to Follow-Up | 1 | 2017 | 79 | 0.04 | Why? |
| Polypharmacy | 1 | 2020 | 347 | 0.04 | Why? |
| Retreatment | 1 | 2017 | 186 | 0.04 | Why? |
| Histoplasmosis | 1 | 2017 | 83 | 0.04 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.04 | Why? |
| Cryptococcosis | 1 | 2017 | 97 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Hematologic Diseases | 1 | 2003 | 614 | 0.04 | Why? |
| Culture | 1 | 2020 | 370 | 0.04 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.04 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.04 | Why? |
| Yttrium | 1 | 1994 | 5 | 0.04 | Why? |
| Disease-Free Survival | 1 | 2020 | 1654 | 0.04 | Why? |
| Erbium | 1 | 1994 | 16 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.04 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.04 | Why? |
| Pulmonary Alveoli | 1 | 2020 | 867 | 0.04 | Why? |
| Vasovasostomy | 1 | 1994 | 2 | 0.04 | Why? |
| Vas Deferens | 1 | 1994 | 6 | 0.04 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.03 | Why? |
| Epididymis | 1 | 1994 | 23 | 0.03 | Why? |
| Seminal Vesicles | 1 | 1994 | 12 | 0.03 | Why? |
| Military Personnel | 1 | 2005 | 1097 | 0.03 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.03 | Why? |
| Genital Diseases, Male | 1 | 1994 | 28 | 0.03 | Why? |
| Aluminum | 1 | 1994 | 71 | 0.03 | Why? |
| Klebsiella pneumoniae | 1 | 2020 | 658 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.03 | Why? |
| Scrotum | 1 | 1994 | 48 | 0.03 | Why? |
| beta-Lactamases | 1 | 2020 | 759 | 0.03 | Why? |
| Dengue Virus | 1 | 2021 | 910 | 0.03 | Why? |
| Sex Factors | 2 | 2021 | 11014 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| Spermatogenesis | 1 | 1994 | 126 | 0.03 | Why? |
| Pulmonary Artery | 1 | 2020 | 803 | 0.03 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.03 | Why? |
| Prostheses and Implants | 1 | 1994 | 116 | 0.03 | Why? |
| Regression Analysis | 1 | 2020 | 2484 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Leishmaniasis, Mucocutaneous | 1 | 2011 | 4 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Bacterial Proteins | 1 | 2020 | 1318 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Leg Ulcer | 1 | 2011 | 32 | 0.03 | Why? |
| Kidney Transplantation | 1 | 2011 | 5397 | 0.03 | Why? |
| Antibodies, Protozoan | 1 | 2011 | 121 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.03 | Why? |
| Antifungal Agents | 1 | 2021 | 1828 | 0.03 | Why? |
| Tongue | 1 | 2011 | 132 | 0.03 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Child | 1 | 2018 | 70012 | 0.02 | Why? |
| Testis | 1 | 1994 | 566 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Self Report | 1 | 2020 | 3802 | 0.02 | Why? |
| Gastrointestinal Diseases | 1 | 2003 | 2580 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2016 | 1158 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 2019 | 2328 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2021 | 7220 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Heart Diseases | 1 | 2003 | 3503 | 0.02 | Why? |
| Coronary Artery Disease | 1 | 2020 | 2570 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Computational Biology | 1 | 2020 | 4514 | 0.02 | Why? |
| Biopsy | 1 | 1994 | 2811 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Hepatitis A | 1 | 1986 | 140 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.02 | Why? |
| Pregnancy | 2 | 1994 | 23879 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Alanine Transaminase | 1 | 1986 | 1329 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.01 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Infant | 1 | 2019 | 30274 | 0.01 | Why? |
| Animals | 1 | 2005 | 78931 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.01 | Why? |
| Hepatovirus | 1 | 1986 | 3 | 0.01 | Why? |
| Follow-Up Studies | 1 | 1986 | 17020 | 0.00 | Why? |